Acasti Pharma Inc. reported unaudited earnings results for the third quarter and year to date ended of November 30, 2016. For the quarter, the company reported net loss of CAD 2.4 million or CAD 0.22 per share against CAD 2.2 million or CAD 0.21 per share a year ago. For the year to date, the company reported net loss of CAD 7.9 million or CAD 0.74 per share against CAD 4.4 million or CAD 0.41 per share a year ago. The higher net loss for the current nine-month period was primarily based on last year's net loss being reduced by a CAD 2.0 million incremental decreased value of derivative warrant liabilities, a CAD 1.0 million change from a foreign exchange gain last year to a foreign exchange loss in the current year, and increased general and administrative expenses.